Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal ...
Spinal and bulbar muscular atrophy (SBMA) is a rare inherited disease that causes progressive muscle weakness and wasting in ...
"Decreasing AMMO [active maximal mouth opening] over time is seen most often in patients with SMA type 2 with an estimated reduction of almost 1 mm per year...At this point, we propose that ...
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical ...
Patients with SMA often suffer from impaired bulbar function, which negatively affects quality of life and can be difficult to treat effectively. A German study prospectively followed children with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nido Biosciences has announced positive results from a ...
Variational AI applies its 𝐄𝐧𝐤𝐢™ generative AI platform to design novel PRMT6 inhibitor scaffolds and discover lead candidates. To ensure rapid execution and reduce downstream attrition, the ...
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results